ARC-02 in B-Cell Lymphoma: NCT07691606 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
140
Planned enrollment
2029-01-01
Primary-completion proxy
Executive view
NCT07691606 evaluates ARC-02 in B-Cell Lymphoma. The disclosed sponsor is Taiho Oncology, Inc., the design is Interventional, and the geographic footprint is United States, Poland, Italy, France, Australia, Spain. The first listed primary endpoint is Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs), assessed over Up to 5 years.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07691606 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider B-Cell Lymphoma landscape. Drug & Asset MCP drug_fetch was queried for ARC-02, while Company & Deal Intelligence MCP organization_fetch was queried for Taiho Oncology, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07691606 | ARC-02 | Phase 1 / Recruiting | Taiho Oncology, Inc. | United States, Poland, Italy, France, Australia, Spain | Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) Up to 5 years | 2029-01-01 |
| NCT07729397 | CD30.CAR-EBVST cell therapy(Baylor College of Medicine) | Phase 1 / Not yet recruiting | The Methodist Hospital Research Institute | United States | Incidence of Dose-Limiting Toxicities (DLTs) From initiation of lymphodepleting chemotherapy through 28 days follo… | 2030-03-31 |
| NCT07649304 | Cyclophosphamide | Phase 1 / Not yet recruiting | National Cancer Institute | Geography not reported | Ability to deliver at least 4 full cycles of glofitamab-rituximab, cyclophosphamide, doxorubicin, vincristine, and pred… Up to cycle 4 (Cycles = 21 days) | 2028-04-30 |
| NCT07638982 | Axatilimab-csfr | Phase 1 / Not yet recruiting | Northside Hospital, Inc. | United States | Determine the recommended Phase 2 dose (RP2D) of axatilimab 1 year | 2028-12-31 |
| NCT07623850 | JLM019 | Phase 1 / Recruiting | Jieke (Tianjin) Biomedical Co Ltd | China | Number of participants with reported Dose-limiting toxicity (DLT) Within 28 days after the first dose | 2029-03-14 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07691606 is a Phase 1, recruiting study with 140 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs)” over “Up to 5 years.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 140 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for B-Cell Lymphoma. These records do not establish direct evidence for NCT07691606 unless the registration number matches.
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circu…
Phase 2; n=46; End of Treatment Complete Response (EOT CR) Rate = 73.3 Percentage of participants (95% Confidence Interval, 58.06 - 85.40) Source: https://clinicaltrials.gov/ct2/show/results/NCT04980222
A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Sub…
Phase 1; n=17; Any TEAEs = 3 Participants ; Any TEAEs = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05075603
Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1; n=13; CR = 84.6 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42490071/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
ARC-02 is indexed as Antibody drug conjugate (ADC) with CD79B biology and a global stage of Phase 1. The asset profile lists Araris Biotech AG as an originator or developer.
Taiho Oncology, Inc. is indexed in United States with the website http://www.taihooncology.com. Taiho Oncology is a pharmaceutical company that specializes in developing innovative cancer treatments. The record lists 11 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether ARC-02 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07691606
Protocol source: https://clinicaltrials.gov/study/NCT07691606
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
ARC-02 in B-Cell Lymphoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) and 2029-01-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
